secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001558370-24-006909
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q1 revenue $17.4M (+12% YoY); FDA clearance for adolescent MDD expands TAM by ~35%
--------------------------------------------------------------------------------

- Revenue $17.4M (+12% YoY); U.S. treatment session revenue $13.0M (+22% YoY) driven by higher utilization.
- Net loss $(7.9)M ($0.27/share) improved from $(10.5)M ($0.38/share) in Q1 2023; EBITDA $(6.3)M vs $(9.4)M.
- NeuroStar received FDA clearance as first-line adjunct TMS for adolescents (15-21) with MDD; total addressable market increased ~35%.
- Shipped 41 systems (vs 49 in Q1 2023); system revenue down 14% due to customer credit challenges and Change Health cyberattack.
- Q2 2024 revenue guidance $18-19M; FY2024 revenue $78-80M; operating expenses $80-84M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/0001558370-24-006909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000155837024006909/stim-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer